{"id":"W2036650093","doi":"10.1007/s10549-014-3015-6","title":"Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study","year":2014,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Bone health and treatments","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"ca_institutions":"Nova Scotia Cancer Centre; Queen Elizabeth II Health Sciences Centre; Centre Hospitalier de l’Université de Montréal; University of Toronto; Sunnybrook Health Science Centre; Grand River Hospital; McMaster University; Ontario Clinical Oncology Group; Princess Margaret Cancer Centre; BC Cancer Agency; Ottawa Hospital; University of Ottawa","funders":"AstraZeneca","keywords":"Medicine; Vandetanib; Internal medicine; Fulvestrant; Breast cancer; Placebo; Oncology; Metastatic breast cancer; Gastroenterology; Cancer; Endocrinology; Estrogen receptor; Pathology; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001519636,0.002824145,0.004182067,0.0005398945,0.0005753562,0.001397518,0.001439905,0.00207853,0.01133362],"category_scores_gemma":[0.002115263,0.001200698,0.001866219,0.0005801313,0.001743946,0.001223249,0.0006002797,0.004125234,0.001939896],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00112266,"about_ca_system_score_gemma":0.001203355,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004163578,"about_ca_topic_score_gemma":0.008801806,"domain_scores_codex":[0.9994942,0.0002082507,0.0000256362,0.0001067279,0.00003413412,0.0001311463],"domain_scores_gemma":[0.9992591,0.0001764642,0.0001787885,0.00009133016,0.00004884837,0.0002454416],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9888368,0.001935264,0.0002514485,0.0003989519,0.0006927336,0.00002066846,0.0000422481,0.0002040382,0.001714572,0.0001167174,0.0007769843,0.005009622],"study_design_scores_gemma":[0.9876929,0.01079734,0.0007232164,0.00001205973,0.0002036615,0.00001151129,0.00001553123,0.00007429893,0.00006917784,0.00007183137,0.0003212717,0.000007090028],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9720273,0.008283122,0.00119832,0.001778496,0.001595819,0.006514465,0.004166606,0.000329999,0.004105906],"genre_scores_gemma":[0.9727676,0.005099968,0.001766255,0.00206078,0.0005652538,0.006114251,0.003023032,0.00006037983,0.008542571],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01133362,"threshold_uncertainty_score":0.03791469,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03084854932691414,"score_gpt":0.3687571923549521,"score_spread":0.3379086430280379,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}